The Anti-Kappa Light Chain Antibody (Ig) from GeneBioSolution is a high-quality antibody validated for immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissues. Kappa light chains are components of immunoglobulins, produced by B lymphocytes and plasma cells, and are critical in the immune response and antibody diversity. This antibody provides sensitive and specific cytoplasmic staining of kappa light chains in plasma cells, with minimal background. It is widely used in diagnostic pathology to assess light chain restriction, an important marker in the diagnosis of plasma cell neoplasms, multiple myeloma, plasmacytomas, and certain B-cell lymphomas. In addition to clinical diagnostics, this antibody is valuable for immunology and hematopathology research, including studies of B-cell development, antibody synthesis, autoimmune disorders, and immunoglobulin subclass distribution. The Anti-Kappa Light Chain Antibody is often used in conjunction with Anti-Lambda Light Chain Antibody to determine kappa/lambda ratios, providing essential information for diagnosing monoclonal vs. polyclonal plasma cell proliferations. All GeneBioSolution antibodies undergo rigorous validation and quality control, ensuring lot-to-lot consistency, reproducible IHC performance, and compatibility with both manual and automated staining systems. Clinical & Research Applications Diagnosis of plasma cell neoplasms, multiple myeloma, and plasmacytomas Evaluation of kappa/lambda light chain restriction in B-cell lymphomas Marker for plasma cells in normal and pathological conditions Research into immunoglobulin synthesis, autoimmune diseases, and B-cell biology
GRM126
GRM126 reacts to the kappa light chain of human immunoglobulins, and does not react to the lambda light chain. GRM126 does not react to monkey (Cyno or Rhesus) IgG, mouse IgG, rat IgG, or goat IgG.
Human IgG
Immunohistochemistry (IHC) Flow Cytometry (FC) Immunocytochemistry (ICC) ELISA
Human.
None
Research Use Only
Stable for 1 Year at -20.0°C from date of receipt.